OTCMKTS:PCLOF PharmaCielo (PCLOF) Stock Price, News & Analysis $0.08 +0.01 (+17.47%) As of 05/19/2026 01:48 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About PharmaCielo Stock (OTCMKTS:PCLOF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PharmaCielo alerts:Sign Up Key Stats Today's Range$0.07▼$0.0850-Day Range$0.03▼$0.0852-Week Range$0.00▼$0.12Volume20,750 shsAverage Volume69,626 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PharmaCielo (OTCMKTS:PCLOF) is a Colombia-based, vertically integrated cannabinoid extraction and manufacturing company that develops pharmaceutical-grade active ingredients for the global medical cannabis market. The company specializes in the cultivation, extraction, purification and isolation of cannabinoids, producing a range of high-purity oils, distillates and isolates that serve as the active pharmaceutical ingredients (APIs) in end-use formulations. PharmaCielo’s product portfolio is designed to meet Good Manufacturing Practices (GMP) standards, enabling partnerships with pharmaceutical firms and wellness brands seeking compliant, consistently standardized cannabinoid inputs. Since commencing operations, PharmaCielo has established a state-of-the-art extraction facility in Colombia, leveraging the country’s favorable agronomic conditions and regulatory framework for medicinal cannabis cultivation. The company’s fully integrated model—from seed to final product—allows for rigorous quality control at each stage, including proprietary winterization and distillation processes that yield >99% purity cannabinoids. In addition to its in-house product offerings, PharmaCielo provides tolling and white-label services for third-party cultivators and brand owners seeking scalable extraction solutions. PharmaCielo’s operations are supported by partnerships with local growers and regulatory authorities, including Colombia’s Ministry of Health and the National Institute for Food and Drug Surveillance. The company primarily serves markets in North America and Europe, where patient demand for medical cannabis and related derivatives continues to expand. PharmaCielo’s ability to navigate the changing regulatory landscape and maintain EU GMP compliance has been central to its strategy of supplying Global Good Agricultural and Collection Practices (GACP)–certified cannabinoid inputs to pharmaceutical and nutraceutical customers. Founded in the mid-2010s and publicly listed in Canada, PharmaCielo has grown its production capacity through phased expansion plans and capital partnerships. The management team combines expertise in pharmaceutical development, agricultural science and international operations to position the company as a reliable supplier of clinical-grade cannabinoids. As global regulators and healthcare providers increasingly recognize the therapeutic potential of cannabis-derived APIs, PharmaCielo aims to leverage its specialized extraction technology and Latin American production base to capture a leading share of the emerging market for standardized cannabinoid products.AI Generated. May Contain Errors. Read More Receive PCLOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCielo and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCLOF Stock News HeadlinesPharmaCielo Pays Debenture Interest in Shares Ahead of April AGMMarch 17, 2026 | tipranks.comPharmaCielo Announces Annual General Meeting and Intention to Issue Interest SharesFebruary 17, 2026 | finance.yahoo.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. | Porter & Company (Ad)PharmaCielo Completes La Margarita Land Sale, Repays Banco Agrario Loan, Strengthens Balance Sheet, Completes AuditOctober 6, 2025 | financialpost.comFPharmaCielo Completes La Margarita Land Sale, Repays Banco Agrario Loan, Strengthens Balance Sheet, Completes AuditOctober 6, 2025 | globenewswire.comPharmaCielo Faces Cease Trade Order Amid Financial Filing DelayAugust 24, 2025 | theglobeandmail.comPharmaCielo Ltd. (PCLOF)December 26, 2024 | finance.yahoo.comPharmaCielo Cannabis Co. Reports 270% YoY Increase In Q3 Revenue, Confident About Profitability In 2025December 2, 2024 | benzinga.comSee More Headlines PCLOF Stock Analysis - Frequently Asked Questions How have PCLOF shares performed this year? PharmaCielo's stock was trading at $0.0372 at the start of the year. Since then, PCLOF stock has increased by 115.1% and is now trading at $0.08. How do I buy shares of PharmaCielo? Shares of PCLOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:PCLOF CIKN/A Webwww.pharmacielo.com Phone(416) 562-3220FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:PCLOF) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredHow to Access Elon’s “Monster” Interest RateMost Americans earn just 0.4% on their savings - that's $40 a year on $10,000. A new banking alternative is of...InvestorPlace | SponsoredThe “tell” for the end of the AI boomThe real question about AI stocks in 2026 isn't whether to own them - it's knowing exactly when to get in and ...Stansberry Research | SponsoredBIGGER than the SpaceX IPO?Jon Najarian believes the SpaceX IPO - potentially arriving as soon as June 12th - may not even be the biggest...Banyan Hill Publishing | SponsoredAfter June 1, don't say I didn't warn youMacroeconomic Strategist Dr. Mark Skousen of The Oxford Club says one date should be at the top of every inves...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCielo Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCielo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.